Terumo Corp
TSE:4543

Watchlist Manager
Terumo Corp Logo
Terumo Corp
TSE:4543
Watchlist
Price: 3 035 JPY -0.78% Market Closed
Market Cap: 4.5T JPY
Have any thoughts about
Terumo Corp?
Write Note

Terumo Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Terumo Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Terumo Corp
TSE:4543
Operating Income
ÂĄ161.3B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
9%
Olympus Corp
TSE:7733
Operating Income
ÂĄ109.4B
CAGR 3-Years
-4%
CAGR 5-Years
6%
CAGR 10-Years
3%
Sysmex Corp
TSE:6869
Operating Income
ÂĄ89.1B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
9%
Nihon Kohden Corp
TSE:6849
Operating Income
ÂĄ17.2B
CAGR 3-Years
-21%
CAGR 5-Years
-1%
CAGR 10-Years
0%
JEOL Ltd
TSE:6951
Operating Income
ÂĄ35.1B
CAGR 3-Years
76%
CAGR 5-Years
37%
CAGR 10-Years
23%
Fukuda Denshi Co Ltd
TSE:6960
Operating Income
ÂĄ23.2B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
No Stocks Found

Terumo Corp
Glance View

Market Cap
4.5T JPY
Industry
Health Care

In the bustling corridors of Tokyo, Terumo Corporation stands as a testament to Japan's prowess in medical innovation, deeply rooted in a legacy that began over 90 years ago. Born from the vision of a group of scientists aiming to improve Japan’s healthcare system, Terumo embarked on its journey by developing high-quality thermometers. This modest start set the stage for what would become a global leader in medical technology. Anchored by its commitment to enhancing patient care and healthcare practices, Terumo carved out a significant niche by focusing on cardiovascular systems, blood transfusion, and cell therapy technologies. As the company grew, it systematically increased its range, moving into areas such as vascular intervention and diabetes care, aligning with evolving medical needs around the globe. Today, Terumo generates its revenue through a multi-faceted business model that thrives on innovation and globalization. It operates through several segments: Cardiovascular, General Hospital, and Blood Management. The Cardiovascular division, a major revenue driver, offers products ranging from stents to heart-lung machines used in cardiac surgeries. Meanwhile, the General Hospital unit provides hospital equipment like infusion pumps and syringe systems, while the Blood Management segment is renowned for its blood and cell processing systems. Terumo’s ability to innovate within these domains enhances its competitive edge by delivering cutting-edge medical solutions. By balancing its expansive product portfolio with a strong focus on research and development, the company not only sustains but frequently advances the standards of modern healthcare, ensuring its continued success in diverse international markets.

Intrinsic Value
2 437.79 JPY
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Terumo Corp's Operating Income?
Operating Income
161.3B JPY

Based on the financial report for Sep 30, 2024, Terumo Corp's Operating Income amounts to 161.3B JPY.

What is Terumo Corp's Operating Income growth rate?
Operating Income CAGR 10Y
9%

Over the last year, the Operating Income growth was 26%. The average annual Operating Income growth rates for Terumo Corp have been 10% over the past three years , 6% over the past five years , and 9% over the past ten years .

Back to Top